Dermatology

These phase 3b findings highlight lebrikizumab’s efficacy and safety in adult and adolescent patients with skin of color living with atopic dermatitis.

This interview features a discussion with Lio regarding pediatric atopic dermatitis and the connection between caregivers, patients, and providers.

This interview with Singh highlights her conference presentation on allergy and its connection to pediatric atopic dermatitis.

This interview highlights 3 new topical non-steroidal options for atopic dermatitis covered in Kircik’s RAD 2025 presentation on FDA approvals.

In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

In this video segment, Kircik described the data highlighted in his JAK inhibitor-related presentation at RAD 2025.

This interview highlights the takeaways from Kircik’s talk at the 2025 RAD Conference regarding JAK inhibitor use and boxed warning concerns.

This video includes a discussion of different procedures designed to help treat patients with hidradenitis suppurativa (HS) and atopic dermatitis.

These findings were announced by Sagimet Biosciences, showing that denifanstat met each of its primary and secondary endpoints in patients with acne.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

During his New Wave Dermatology interview, Naveed Sami, MD, spoke about additional takeaways from his session on the cutaneous effects of immunotherapies.

In this interview at the New Wave Dermatology meeting, Naveed Sami, MD, highlights some of the notable takeaways from his talk on the impacts of immunotherapies.

This Month in Review summary includes a list of some of the most notable or impactful news in the dermatology field from May 2025.

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

The May 30, 2025 SOCS News Update highlights cosmetic concerns among patients with skin of color.

This summary features a variety of abstracts to be presented at the RAD meeting in June 2025, highlighting new data in atopic dermatitis and the dermatology space in general.

Amy Spizuoco, DO, joins the show to discuss her journey as a key opinion leader in dermatology.

Elizabeth Hale, MD, discusses the need to improve awareness and diagnosis of actinic keratosis.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and innovative treatments, in this week's essential news roundup for professionals.

Discover innovative treatments for plaque psoriasis that cater to diverse skin tones, offering effective relief without the risk of discoloration.

This approval of roflumilast foam as a once-daily topical treatment for psoriasis of the scalp and body followed the phase 3 ARRECTOR study findings.

AC-201 at 25, 50, and 100 mg doses show promising phase 2 results, significantly reducing psoriasis severity.

Miranti shared 2025 acne and rosacea trends, as well as an overlapping treatment option for patients with both conditions, at New Wave Dermatology.